Main
tumor necrosis
MULTIPLE MYELOMA, DISEASE PROGRESSION, TUMOR NECROSIS, MYELOMA, REFRACTORY MULTIPLE MYELOMA
The introduction of immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies has transformed the treatment landscape in multiple myeloma. The addition of these agents has substantially improved patient survival; however, outcomes for patients with disease progression after these agents remain poor with a median progression-free survival (PFS) of 4.6 months and median overall survival (OS) of 12.4 months with a standard of care therapy, highlighting an unmet medical need in the relapsed or refractory multiple myeloma populationB-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, is highly expressed on malignant plasma cells, making it an ideal target for the treatment of multiple myelomaElranatamab (PF-06863135) is a humanized bispecific antibody that targets both BCMA (on myeloma cells) and CD3 (on T cells)The registrational phase 2 MagnetisMM-3 study (